Skip to content

NIH Websites Are Changing

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
299 items
NIH study raises doubt about any benefits omega-3 and dietary supplements like these may have for cognitive decline. (Photo courtesy of NEI)

NIH Study Shows no Benefit of Omega-3 or Other Nutritional Supplements for Cognitive Decline

While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons.
Images of the brain generated by diffusion tensor imaging, a type of MRI. The red highlights show visual pathways in the brain that deteriorate in patients with LCA, but appear to improve with gene therapy to the retina. Credit: Dr. Manzar Ashtari, University of Pennsylvania.

With LCA Gene Therapy, a Rare Glimpse of the Adult Brain Adapting to New Experience

When people lose the ability to see, how do the visual parts of the brain change in response? And if they regain their sight, are the changes reversed?
Children who slept near a cooking fire were four times as likely to develop severe trachoma compared with children who slept in ventilated rooms without cooking fires. This child’s severe trachoma led to loss of vision in his left eye. Photo courtesy of Raul Vasquez/Orbis.

Trachoma Risk Tied to Sleeping Near Cooking Fires, Lack of Ventilation

Children who sleep in unventilated rooms with cooking fires are at greater risk for severe trachoma, a leading cause of preventable blindness in developing countries.
Grantee News

Mind Over Matter

Through a clinical collaboration, a 34-year-old paralyzed from the neck down is the first person in the world to have a neural prosthetic device implanted in a region of the brain where intentions are made.
Grantee News

Patients with AIDS at Increased Risk of Developing Age-Related Macular Degeneration

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV.
LCA is an inherited disorder that causes vision loss in childhood. It primarily affects the functioning of the retina, the light-sensitive tissue at the back of the eye, as shown here. Photo credit: National Eye Institute

NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy

Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients’ eyesight and the sensitivity of the retina within weeks of treatment.
Eye Examination

Early Tight Blood Glucose Control Reduces Eye Surgeries in People with Type 1 Diabetes

People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease, versus those who do not, are 48 percent less likely to need eye surgery, and the total number of such surgeries is 37 percent less.
Grantee News

Rare Mutation Causes Vitamin A Deficiency and Eye Deformities

Researchers at the University of Michigan and UC Davis have solved a genetic mystery that has afflicted three unrelated families, and possibly others, for generations.
Cross-sectional images of retina from retinoschisin-deficient mice, untreated and treated with XLRS gene therapy.

NEI Human Gene Therapy Trial for Retinoschisis Underway

The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in...
Illustration showing the retina as seen through a dilated pupil.

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse.